Toggle menu

3MG Trial

Start date:
Historic
End date:
June 2012
Co-ordinated by:
University of Sheffield

A randomised trial of intravenous or nebulised magnesium sulphate versus placebo for acute severe asthma.

 

Aim

To assess the effectiveness of IV and nebulised magnesium sulphate in the treatment of acute severe asthma.

Trial Design

Multi centre randomised controlled trial of intravenous (IV) or nebulised magnesium sulphate versus placebo for acute severe asthma

Chief Investigator

Professor Steve Goodacre

Local PI

Professor Alasdair Gray

List of Publications – references

S Goodacre, J Cohen, M Bradburn, A Gray, J Benger, T Coats on behalf of the 3Mg Research Team. The 3Mg Trial: Randomised controlled trial of intravenous or nebulised magnesium sulphate or standard therapy for severe acute asthma. The Lancet Respiratory Medicine. (2013); 1:293 – 300.

Goodacre S, Cohen J, Bradburn M, Stevens J, Gray A, Benger J, et al. The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. . Health Technology Assessment. (2014);18(22).

Local PI

Professor Alasdair Gray

Honorary Professor of Emergency Medicine & Clinical Director of the Emergency Department

More EMERGE Trials

Prospective multicentre observational study conducted over one calendar month in 2019, with the aim of describing the epidemiology of non-trauma related headache in adults presenting to emergency departments including investigations, treatments and outcome.

This will include adult patients presenting to the ED with non-trauma-related headache as their primary complaint.

Read more

HEAD Study

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)

Read more

ATTEST2 Trial

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)

TARGET CTCA is a joint venture between EMERGE and the cardiology research team aiming to recruit patients with suspected ACS across NHS Lothian and NHS Greater Glasgow and Clyde. The study aims to recruit 2270 participants. For further information, please contact the EMERGE team.

Read more

TARGET-CTCA Trial